VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT) announces that,
pending regulatory approval, it intends to issue 60,000 common shares in the
capital of VentriPoint (the "Commons Shares") to non-officer directors of
VentriPoint for payment of services rendered from July 2008 to August 2008.
VentriPoint also proposes to issue 364,159 Common Shares to two consultants for
services rendered from July 2008 to December 2008 in satisfaction of outstanding
debts. The Common Shares will be issued at a deemed price of $0.145 per share to
the non-officer directors and consultants and will have a hold period of four
months from the date of issuance in accordance with applicable securities
legislation. 


VentriPoint also announces that it proposes to issue 555,454 Common Shares at a
deemed price of $.165 per share to its development team as part of the Company's
incentive program in lieu of cash payments. The Common Shares issued to the
development team will be subject to regulatory approval and the securities
issued will be subject to a four month hold period from the date of issuance in
accordance with applicable securities legislation.


About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease -
the number one cause of death in developed countries. By using images produced
from existing medical imaging systems, the VentriPoint Medical System ("VMS")
generates critical heart measurements in a rapid and inexpensive manner not
currently available. Health Canada has granted licensed approval for the VMS
breakthrough diagnostic tool which is based upon technology received by
VentriPoint through its exclusive technology license with the University of
Washington. The VMS, together with its associated online service, is being
developed for a variety of heart related disease states, including congenital
heart disease and pulmonary hypertension.


To receive press release, please email chris@chfir.com and mention VentriPoint
in the Subject line. 


FORWARD-LOOKING STATEMENTS: The statements made in this press release that are
not historical facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical facts, which
address VentriPoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. The
Corporation undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof, or to reflect the
occurrence of any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be given that
these expectations will materialize.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vortex Metals Charts.
Vortex Metals (TSXV:VMS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vortex Metals Charts.